Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 230.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 214,878 shares of the company’s stock after buying an additional 149,864 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Eton Pharmaceuticals were worth $2,862,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Wasatch Advisors LP acquired a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth about $1,431,000. Baader Bank Aktiengesellschaft acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $373,000. Jane Street Group LLC purchased a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $90,000. Geode Capital Management LLC boosted its holdings in shares of Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after buying an additional 32,365 shares in the last quarter. Finally, Anchor Capital Advisors LLC purchased a new position in shares of Eton Pharmaceuticals in the 4th quarter valued at $805,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ETON has been the subject of several research analyst reports. HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Craig Hallum upped their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, B. Riley started coverage on Eton Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $21.00 price target on the stock.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $15.29 on Tuesday. The company has a market capitalization of $398.32 million, a P/E ratio of -69.50 and a beta of 1.37. Eton Pharmaceuticals, Inc. has a 1 year low of $3.03 and a 1 year high of $18.41. The company’s fifty day moving average is $15.40 and its two-hundred day moving average is $11.35.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.